Zobrazeno 1 - 10
of 234
pro vyhledávání: '"Paul E. Stang"'
Autor:
Robert B. Penfold, David S. Carrell, David J. Cronkite, Chester Pabiniak, Tammy Dodd, Ashley MH Glass, Eric Johnson, Ella Thompson, H. Michael Arrighi, Paul E. Stang
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Patients and their loved ones often report symptoms or complaints of cognitive decline that clinicians note in free clinical text, but no structured screening or diagnostic data are recorded. These symptoms/complaints may be signa
Externí odkaz:
https://doaj.org/article/73ad7e3a31144549b1af37d67416973c
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0226255 (2019)
BackgroundConfounding by disease severity is an issue in pharmacoepidemiology studies of rheumatoid arthritis (RA), due to channeling of sicker patients to certain therapies. To address the issue of limited clinical data for confounder adjustment, a
Externí odkaz:
https://doaj.org/article/188c87584f184cb5a5251cb5efb04e52
Autor:
Jill Hardin, Erica A. Voss, Hany Rofael, Patrick B. Ryan, Paul E. Stang, Daniel Fife, Ira D. Solomon
Publikováno v:
Neuropsychopharmacology Reports
Aim To assess label compliance in prescription of medications approved for treatment of attention‐deficit/hyperactivity disorder (ADHD) in Japan at the time of this study: methylphenidate (MPH), atomoxetine, and guanfacine. Methods Retrospective de
Autor:
Kiyoshi Kubota, Paul E. Stang, Ian C. K. Wong, Yea Huei Kao Yang, Kenneth K.C. Man, Yukari Kamijima, Yinghong Zhang, Chien Chou Su, Chantelle Hardy, Patrick B. Ryan, Martijn J. Schuemie, Soko Setoguchi, Shinya Kimura, Edward Chia Cheng Lai
Publikováno v:
Journal of Psychiatric Research. 131:77-84
The use of antipsychotic medications (APMs) could be different among countries due to availability, approved indications, characteristics and clinical practice. However, there is limited literature providing comparisons of APMs use among countries. T
Autor:
Frank J. DeFalco, Martijn J. Schuemie, John B. Buse, Paul E. Stang, Zhong Yuan, Patrick B. Ryan, Norman Rosenthal, Jesse A. Berlin
Publikováno v:
Diabetes, Obesity and Metabolism. 20:2585-2597
Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some have reported risk of below-knee lower extremity (BKLE) amputation. This st
Publikováno v:
Depression and Anxiety
Background Depression that does not respond to antidepressants is treatment-resistant depression (TRD). TRD definitions include assessments of treatment response, dose and duration, and implementing these definitions in claims databases can be challe
Autor:
Mehul Desai, Zhong Yuan, Paul E. Stang, Frank J. DeFalco, Norm Rosenthal, Patrick B. Ryan, Martijn J. Schuemie, Jesse A. Berlin
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To examine the incidence of amputation in patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose co‐transporter 2 (SGLT2) inhibitors overall, and canagliflozin specifically, compared with non‐SGLT2 inhibitor antihyperglyca
Autor:
Robert B. Penfold, David S. Carrell, David J. Cronkite, Chester Pabiniak, Tammy Dodd, Ashley MH Glass, Eric Johnson, Ella Thompson, H. Michael Arrighi, Paul E. Stang
Publikováno v:
BMC medical informatics and decision making. 22(1)
Background Patients and their loved ones often report symptoms or complaints of cognitive decline that clinicians note in free clinical text, but no structured screening or diagnostic data are recorded. These symptoms/complaints may be signals that p
Publikováno v:
Heliyon, Vol 5, Iss 3, Pp e01198-(2019)
Autor:
Kiyoshi Kubota, Edward Chia Cheng Lai, Yea Huei Kao Yang, Soko Setoguchi, Paul E. Stang, Ian C. K. Wong
Publikováno v:
Current Epidemiology Reports. 2:229-238
With the rapid progress of computer technology and development of electronic health records, pharmacoepidemiologic studies using multiple databases across and within nations have become feasible and popular in recent years. Multinational pharmacoepid